8-K: ArriVent Firmonertinib Shows Strong Phase 1b Lung Cancer Data

ArriVent BioPharma presented positive final data from its global Phase 1b study of firmonertinib monotherapy in EGFR PACC mutant non-small cell lung cancer.

Summary

• Final analysis of firmonertinib monotherapy data from a global Phase 1b study in EGFR PACC mutant non-small cell lung cancer (NSCLC) was presented at the 2025 World Conference on Lung Cancer.
• The study demonstrated a median progression-free survival (mPFS) of 16.0 months with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients.
• Confirmed overall response rate (cORR) was 68.2% and median duration of response (DOR) was 14.6 months by BICR in first-line patients.
• Confirmed central nervous system (CNS) responses, including complete responses (CRs), were observed by BICR.
• Firmonertinib rapidly decreased or cleared PACC circulating tumor DNA (ctDNA) in frontline patients across various PACC mutation types (frequent, less frequent, and compound PACC).
• Enrollment of the first patient in the global pivotal Phase 3 ALPACCA study in first-line EGFR PACC mutant NSCLC is expected in the second half of 2025.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data for firmonertinib in an area of significant unmet medical need, demonstrating strong efficacy and a consistent safety profile. This significantly de-risks the development program and sets a positive outlook for the upcoming Phase 3 trial.

Positives

• 16.0 months median progression-free survival (mPFS) with firmonertinib 240 mg by BICR in first-line patients, with the majority of patients remaining on study.
• 68.2% confirmed overall response rate (cORR) and 14.6 months median duration of response (DOR) by BICR at 240 mg in first-line patients.
• Confirmed CNS responses, including 42.9% CNS confirmed ORR and 35.7% CNS confirmed CRs in CNS evaluable disease front-line patients by BICR.
• Rapid decrease or clearance of PACC ctDNA in 82% (240 mg) and 79% (160 mg) of frontline PACC patients with detectable ctDNA at baseline.
• Responses observed across a wide range of EGFR PACC mutations, including frequent (G719X, S768I), less frequent (E709X, V774M), and compound mutations.
• Safety profile continues to be generally well-tolerated and manageable, with no new safety signals observed over longer treatment duration, consistent with the EGFR-TKI class.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
• Actual results could differ due to factors described in the 'Risk Factors' section of the annual report on Form 10-K for the fiscal year ended December 31, 2024, filed on March 3, 2025, and other SEC filings.

Future Outlook

ArriVent expects to enroll the first patient in its global registrational ALPACCA Phase 3 trial for frontline PACC patients in the second half of 2025. Topline data from the global Phase 3 FURVENT trial for firmonertinib in first-line NSCLC patients with EGFR exon 20 insertion mutations is expected in early 2026.

Management Comments

• "Our 16-month prolonged progression free survival with once daily oral firmonertinib monotherapy has been maintained with 16.5 months of median follow up and we are particularly encouraged by the CNS responses including CNS complete responses." Bing Yao, Ph.D., Chairman and Chief Executive Officer of ArriVent.
• "Together this data reinforces the potential of firmonertinib to address key unmet needs in the global EGFR mutant NSCLC treatment landscape." Bing Yao, Ph.D.
• "Additionally, the rapid clearance of PACC ctDNA in frontline patients observed across a broad range of PACC mutations, including those with frequent, less frequent and compound PACC mutations, is consistent with the broad activity of firmonertinib in PACC mutant NSCLC." Bing Yao, Ph.D.
• "We expect to enroll the first patient in our global registrational ALPACCA Phase 3 trial in frontline PACC patients in the second half of the year." Bing Yao, Ph.D.

Industry Context

Lung cancer is the leading cause of cancer-related deaths globally, with NSCLC accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent event, and uncommon EGFR mutations like PACC (approximately 12% of all EGFR mutations) and exon 20 insertion mutations (approximately 9%) represent a significant unmet medical need due to lower life expectancy with available therapies and limited treatment options. Firmonertinib's positive data in PACC mutations positions it as a potential solution in this underserved segment, addressing a critical gap in the global EGFR mutant NSCLC treatment landscape.

Comparison to Industry Standards

• Patients with NSCLC whose tumors harbor uncommon EGFR mutations, such as PACC mutations, have significantly lower life expectancy with available therapies and represent an area of unmet medical need.
• There is no broadly utilized standard of care treatment for first-line PACC mutant patients, highlighting the potential for firmonertinib to fill this void.
• The FURVENT trial compares firmonertinib to platinum-based chemotherapy with pemetrexed, which is the current first-line standard of care for NSCLC patients with EGFR exon 20 insertion mutations.
• Firmonertinib's 16.0 months mPFS and 68.2% cORR in first-line PACC patients suggest a potentially superior or highly competitive profile compared to the limited existing options for this specific mutation type.

Stakeholder Impact

• Shareholders: Positive clinical data is highly likely to increase investor confidence and potentially the company's valuation due to the de-risking of a key pipeline asset.
• Patients: Offers a promising new treatment option for a difficult-to-treat subset of NSCLC patients with EGFR PACC mutations, addressing a significant unmet medical need.
• Medical Community: Provides new evidence for the efficacy of firmonertinib, potentially influencing future treatment guidelines and research in EGFR mutant NSCLC.

Next Steps

• Enrollment of the first patient in the global pivotal Phase 3 ALPACCA study in first-line EGFR PACC mutant NSCLC in the second half of 2025.
• Expected topline data from the global Phase 3 FURVENT trial in early 2026.
• Continued study of firmonertinib in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations, in partnership with Beijing InnoCare Pharma Tech Co., Ltd.

Key Dates

Recommendation

The positive final Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC, demonstrating strong mPFS, cORR, and CNS responses, significantly de-risks the asset. Given the substantial unmet medical need in this patient population and the drug's broad activity, the initiation of a pivotal Phase 3 study positions ArriVent for potential market leadership. This strong clinical validation, coupled with a manageable safety profile, makes ArriVent a compelling investment opportunity for long-term growth.

Keywords

ArriVent BioPharma, firmonertinib, NSCLC, non-small cell lung cancer, EGFR, PACC mutations, Phase 1b, clinical trial, oncology, biopharma, lung cancer, targeted therapy, ALPACCA, FURVENT, TKI, tyrosine kinase inhibitor